Semaglutide Research for Weight Loss
An evidence-based overview of research examining Semaglutide in the context of weight loss. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide is FDA-approved for chronic weight management (as Wegovy) and has demonstrated substantial efficacy in multiple Phase 3 trials. The STEP 1 trial showed 14.9% mean weight loss versus 2.4% with placebo at 68 weeks (N=1,961). The mechanism involves GLP-1 receptor activation in appetite-regulating brain regions, reducing hunger and increasing satiety. Higher dose studies (STEP UP, 7.2mg) achieved 20.7% weight loss. Approximately 50% of participants achieve 15% or greater weight loss. Semaglutide represents a significant advance in pharmacological obesity treatment. However, weight tends to return after discontinuation (STEP 4 showed 2/3 of lost weight regained within a year of stopping), suggesting long-term treatment may be necessary.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Weight Loss
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.